Coronavirus Case Treated With Gilead Drug May Spur Wider Tests
- Pneumonia patient in Washington state improved after infusion
- Gilead drug was developed for Ebola, but may fight 2019-nCoV
The Providence Regional Medical Center in Everett.
Photographer: David Ryder/BloombergThis article is for subscribers only.
The first reported use of an experimental Gilead Sciences Inc. drug to fight the novel coronavirus has encouraged doctors to support further testing of the medication.
Gilead’s remdesivir was given to the first U.S. case, a 35-year-old man who developed pneumonia after he tested positive for the 2019-nCoV virus and was hospitalized in an airborne-isolation unit at Providence Regional Medical Center Everett in Washington state for observation.